Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Cardiovascular
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
BMS/Pfizer's apixaban emerges as a strong anti-coagulation contender
01 September 2010
Bristol-Myers Squibb's apixaban beat aspirin (acetylsalicylic acid) for the prevention of venous thromboembolism (VTE) in patients at high-risk of atrial fibrillation (AF) who were unable to take warfarin, show Phase III results presented at the ...
Glenmark unveils details of its TRPA1 antagonist
31 August 2010
Glenmark Pharmaceuticals is developing a TRPA1 receptor antagonist for pain and respiratory disorders. The Indian company joins at least four other firms including Hydra Biosciences, Abbott and Janssen that are known to be working in the same ...
NICE gives AF patients more options with Sanofi-Aventis's Multaq
26 August 2010
NICE, the National Institute for Health and Clinical Excellence in the UK, yesterday published final guidance recommending Sanofi-Aventis's Multaq (dronedarone) as a second-line treatment for patients with atrial fibrillation. Eligible patients will ...
FDA reviews "possible" CV risks with Parkinson's drug Stalevo
23 August 2010
The US FDA has notified healthcare professionals that it is reviewing clinical trial data that suggests that patients taking Orion/Novartis's Parkinson's disease treatment Stalevo (a combination formulation of carbidopa, levodopa and entacapone) may ...
ARYx secures runway until year end as it seeks crucial deal
17 August 2010
ARYx Therapeutics has secured a bridge financing that should fund operations until the end of the year. In February ARYx said that advanced discussions regarding the licensing of its oral anti-arrhythmic agent, budiodarone, had ended without a deal ...
 
2010 Scrip 100 - Pharma muscles into emerging markets with M&A
23 August 2010
This year has seen many firms facing patent expiries on core revenue generators. The current climate is driving M&A strategies, particularly in emerging markets and often with a focus on branded ...
2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010
Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and the approval of first-in-class therapeutics such as Amgen's Prolia and Dendreon's Provenge: the first ...
Simplifying dose regimens - new clarity in patenting procedures
13 July 2010
Recent legislative changes and court rulings have resulted in a simpler and more coherent approach to the patenting of new dosage regimens in Europe. Mark Chacksfield looks at the history of the ...
 
GE Healthcare aims to end unpredictability in early drug research
Better consistency of the cells used in early-stage drug research could save R&D departments millions of dollars and a lot of wasted time and effort. At GE Healthcare, the commercialisation of ...
Amarin focused on CV disease to pump new life into company
24 February 2010
The fundraising that saved Amarin from financial woes last years appear to have given the company a new lease of life. Its interim CEO Dr Declan Doogan told Scrip of his confidence for the company's ...
Anti-obesity drugs: an inventor's perspective
20 November 2009
After years of anti-obesity disappointments, Orexigen's Contrave, Vivus's Qnexa and Arena's lorcaserin stand on the verge of being filed with the US FDA. Professor Michael Cowley, inventor of ...
 
Private investment round-up: July 2010 - highest monthly investments secured so far this year
18 August 2010
A Scrip analysis has identified 21 companies that raised private investment in July, one up on the previous month, but a 41% increase in the funds raised to $540 million compared with June. . The ...
Questions linger over US comparative effectiveness funding
24 February 2009
The economic stimulus bill signed into law by US President Barack Obama on February 17th provides a $1.1 billion bolus to government agencies for comparative effectiveness research on medical ...
Life under FDAAA: Four months of post-approval studies and REMS
01 August 2008
The FDA has not hesitated to use its new safety powers since they took effect on March 25th. A review of original and supplemental NDA and BLA approval letters on the FDA's website indicates that, ...
 
Vitamin D and the vasculature: can we teach an old drug new tricks?
13 May 2009
Background: Vitamin D is a steroid hormone known for its role in regulating levels of calcium and phosphorus. Vitamin D has important autocrine/paracrine roles and it is involved in vascular biology. ...
Autophagy: a target for therapeutic interventions in myocardial pathophysiology
01 December 2008
Background: Autophagy is a major degradative and highly conserved process in eukaryotic cells that is activated by stress signals. This self-cannibalisation is activated as a response to changing ...
A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration
01 December 2008
Objective: Amplification of inflammatory response in the non-infarct area plays an important role in the pathogenesis of ventricular remodeling after myocardial ischemia. Activation of nuclear ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm